NEW YORK ( TheStreet) -- "Mad Money" Research Director Nicole Urken met with TheStreet's Jim Cramer to discuss some powerful cancer-fighting procedures that have begun to emerge.
With the American Society of Clinical Oncology conference wrapping up this week in Chicago, some old-name pharmaceutical stocks are getting a boost for their recent progress on cancer-fighting techniques.
The new PD-1 procedure, which involves using the patient's immune system to target and fight cancerous cells, hasn't seemed to gain much traction until now.This technique is something that Gilead (GILD - Get Report) is looking at, even though the company has been focused on treating HIV and hepatitis C. BioMarin (BMRN - Get Report) is also looking at entering the space. "These are all positive names with long-term drivers," Urken said, adding that they are "also helping improve people's lives and fight disease." -- Written by Bret Kenwell in Petoskey, Mich.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts